Current survival measures reliably reflect modern sequential
treatment in CML: Correlation with prognostic stratifications

J 2013

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA et. al.

Základní údaje

Originální název

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Autoři

PAVLÍK, Tomáš (203 Česká republika, garant, domácí), Eva JANOUŠOVÁ (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), Karel INDRÁK (203 Česká republika), Marie JAROSOVA (203 Česká republika), Hana KLAMOVA (203 Česká republika), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Jaroslava VOGLOVÁ (203 Česká republika), Edgar FABER (203 Česká republika), Michal KARAS (203 Česká republika), Katerina POLAKOVA MACHOVA (203 Česká republika), Zdeněk RÁČIL (203 Česká republika, domácí), Eva DEMEČKOVÁ (703 Slovensko), Ludmila DEMITROVIČOVÁ (703 Slovensko), Elena TOTHOVÁ (703 Slovensko), Juraj CHUDEJ (703 Slovensko), Imrich MARKULJAK (703 Slovensko), Eduard CMUNT (203 Česká republika), Tomas KOZAK (203 Česká republika), Jan MUŽÍK (203 Česká republika, domácí) a Ladislav DUŠEK (203 Česká republika, domácí)

Vydání

American Journal of Hematology, Hoboken, Wiley-Blackwell, 2013, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.477

Kód RIV

RIV/00216224:14110/13:00069543

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/ajh.23508

UT WoS

000323313500013

Klíčová slova anglicky

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; COMPLETE CYTOGENETIC RESPONSE; CHRONIC-PHASE; BCR-ABL; MOLECULAR RESPONSE; IMATINIB MESYLATE; INTERFERON-ALPHA; THERAPY; FAILURE

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 2. 2014 10:53, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks.

Citovat

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA, Hana KLAMOVA, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVÁ, Edgar FABER, Michal KARAS, Katerina POLAKOVA MACHOVA, Zdeněk RÁČIL, Eva DEMEČKOVÁ, Ludmila DEMITROVIČOVÁ, Elena TOTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Tomas KOZAK, Jan MUŽÍK a Ladislav DUŠEK. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. American Journal of Hematology. Hoboken: Wiley-Blackwell, 2013, roč. 88, č. 9, s. 790-797. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.23508.

@article{1124313,
   author = {Pavlík, Tomáš and Janoušová, Eva and Mayer, Jiří and Indrák, Karel and Jarosova, Marie and Klamova, Hana and Žáčková, Daniela and Voglová, Jaroslava and Faber, Edgar and Karas, Michal and Polakova Machova, Katerina and Ráčil, Zdeněk and Demečková, Eva and Demitrovičová, Ludmila and Tothová, Elena and Chudej, Juraj and Markuljak, Imrich and Cmunt, Eduard and Kozak, Tomas and Mužík, Jan and Dušek, Ladislav},
   article_location = {Hoboken},
   article_number = {9},
   doi = {http://dx.doi.org/10.1002/ajh.23508},
   keywords = {CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; COMPLETE CYTOGENETIC RESPONSE; CHRONIC-PHASE; BCR-ABL; MOLECULAR RESPONSE; IMATINIB MESYLATE; INTERFERON-ALPHA; THERAPY; FAILURE},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications},
   volume = {88},
   year = {2013}
}

TY  - JOUR
ID  - 1124313
AU  - Pavlík, Tomáš - Janoušová, Eva - Mayer, Jiří - Indrák, Karel - Jarosova, Marie - Klamova, Hana - Žáčková, Daniela - Voglová, Jaroslava - Faber, Edgar - Karas, Michal - Polakova Machova, Katerina - Ráčil, Zdeněk - Demečková, Eva - Demitrovičová, Ludmila - Tothová, Elena - Chudej, Juraj - Markuljak, Imrich - Cmunt, Eduard - Kozak, Tomas - Mužík, Jan - Dušek, Ladislav
PY  - 2013
TI  - Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
JF  - American Journal of Hematology
VL  - 88
IS  - 9
SP  - 790-797
EP  - 790-797
PB  - Wiley-Blackwell
SN  - 03618609
KW  - CHRONIC MYELOID-LEUKEMIA
KW  - TYROSINE KINASE INHIBITORS
KW  - COMPLETE CYTOGENETIC RESPONSE
KW  - CHRONIC-PHASE
KW  - BCR-ABL
KW  - MOLECULAR RESPONSE
KW  - IMATINIB MESYLATE
KW  - INTERFERON-ALPHA
KW  - THERAPY
KW  - FAILURE
N2  - Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks.
ER  -

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA, Hana KLAMOVA, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVÁ, Edgar FABER, Michal KARAS, Katerina POLAKOVA MACHOVA, Zdeněk RÁČIL, Eva DEMEČKOVÁ, Ludmila DEMITROVIČOVÁ, Elena TOTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Tomas KOZAK, Jan MUŽÍK a Ladislav DUŠEK. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. \textit{American Journal of Hematology}. Hoboken: Wiley-Blackwell, 2013, roč.~88, č.~9, s.~790-797. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.23508.

Podrobný výpis o publikaci